The first of the anticipated “rebalancing” therapies, Pfizer’s marstacimab (Hympavzi®), an anti-TFPI recombinant monoclonal antibody, was approved by the FDA in October 2024 for use in hemophilia A and B patients without inhibitors. Click here for the AJMC news release (American Journal of Managed Care).